NCT07439120
Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors
StatusRecruiting
PhaseEarly Phase 1
Primary completion (estimated)
At risk: Primary completion moved 4 months later.
See at-risk trials from Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 26 words
- Primary and study completion pushed from Aug 31, 2026 to Dec 31, 2026
- Interventions: ⁶⁸Ga/¹⁷⁷Lu-BRP-020063 (Drug) to ⁶⁸Ga/¹⁷⁷Lu-BRP-020063 (Drug)
- Secondary endpoints: details revised at 1 of 3 entries
- Notable Recruitment opened
- Study sites: 0 to 1
- Start date changed from estimate of Mar 2, 2026 to Apr 13, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Adeverse Events
Timeframe: From enrolment to 4 weeks after the first dose
Secondary (3)
PK Parameters
Biodistribution
Radiation Dosimetry
Arms and interventions
⁶⁸Ga/¹⁷⁷Lu-BRP-020063 Treatment ArmExperimental
Drugs: ⁶⁸Ga/¹⁷⁷Lu-BRP-020063
Sites
1 site in 1 country
- Shanghai General HospitalShanghai, China